Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial

BACKGROUND: Emerging clinical data suggest that an immune checkpoint inhibitor in combination with an antiangiogenic agent is a reasonable strategy for multiple malignancies. We assessed the combination of camrelizumab with apatinib in pretreated advanced primary liver cancer (PLC, cohort A) from a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mei, Kuimin, Qin, Shukui, Chen, Zhendong, Liu, Ying, Wang, Linna, Zou, Jianjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986650/
https://www.ncbi.nlm.nih.gov/pubmed/33741732
http://dx.doi.org/10.1136/jitc-2020-002191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986650/
https://www.ncbi.nlm.nih.gov/pubmed/33741732
http://dx.doi.org/10.1136/jitc-2020-002191

Ejemplares similares